Covalon Technologies Ltd. (CVALF)
USD 1.7
(1.8%)
USD 1.7
(1.8%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 14.36 Million CAD | 91.66% |
| 2022 | 7.49 Million CAD | -22.72% |
| 2021 | 9.69 Million CAD | -22.34% |
| 2020 | 12.48 Million CAD | -42.78% |
| 2019 | 21.82 Million CAD | 10.97% |
| 2018 | 19.66 Million CAD | -6.41% |
| 2017 | 21.01 Million CAD | 406.19% |
| 2016 | 4.15 Million CAD | -12.72% |
| 2015 | 4.75 Million CAD | -27.75% |
| 2014 | 6.58 Million CAD | 215.15% |
| 2013 | 2.08 Million CAD | 42.6% |
| 2012 | 1.46 Million CAD | 11.89% |
| 2011 | 1.3 Million CAD | -4.9% |
| 2010 | 1.37 Million CAD | 25.86% |
| 2009 | 1.09 Million CAD | -33.61% |
| 2008 | 1.64 Million CAD | 283.74% |
| 2007 | 429.26 Thousand CAD | 7.71% |
| 2006 | 398.52 Thousand CAD | 0.0% |
| 2005 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 5.24 Million CAD | 6.07% |
| 2024 Q1 | 2.66 Million CAD | -7.94% |
| 2024 Q2 | 5.12 Million CAD | 92.46% |
| 2023 Q2 | 4.17 Million CAD | 12.92% |
| 2023 Q4 | 2.89 Million CAD | -19.81% |
| 2023 Q3 | 3.6 Million CAD | -13.6% |
| 2023 FY | 14.36 Million CAD | 91.66% |
| 2023 Q1 | 3.69 Million CAD | 181.76% |
| 2022 Q3 | 2.14 Million CAD | 23.29% |
| 2022 Q4 | 1.31 Million CAD | -38.94% |
| 2022 Q2 | 1.74 Million CAD | -24.01% |
| 2022 Q1 | 2.29 Million CAD | 187.23% |
| 2022 FY | 7.49 Million CAD | -22.72% |
| 2021 Q2 | 3.64 Million CAD | 1.59% |
| 2021 Q1 | 3.58 Million CAD | 97.71% |
| 2021 Q3 | 5.09 Million CAD | 39.92% |
| 2021 FY | 9.69 Million CAD | -22.34% |
| 2021 Q4 | -2.62 Million CAD | -151.57% |
| 2020 Q4 | 1.81 Million CAD | -40.44% |
| 2020 FY | 12.48 Million CAD | -42.78% |
| 2020 Q2 | 2.79 Million CAD | -42.26% |
| 2020 Q1 | 4.83 Million CAD | 22.88% |
| 2020 Q3 | 3.04 Million CAD | 9.05% |
| 2019 Q3 | 4.03 Million CAD | -56.31% |
| 2019 Q2 | 9.24 Million CAD | 100.77% |
| 2019 Q1 | 4.6 Million CAD | 7.48% |
| 2019 FY | 21.82 Million CAD | 10.97% |
| 2019 Q4 | 3.93 Million CAD | -2.56% |
| 2018 Q1 | 4.53 Million CAD | -37.35% |
| 2018 Q2 | 4.33 Million CAD | -4.5% |
| 2018 Q3 | 6.5 Million CAD | 50.11% |
| 2018 Q4 | 4.28 Million CAD | -34.16% |
| 2018 FY | 19.66 Million CAD | -6.41% |
| 2017 Q2 | 4.7 Million CAD | 5.36% |
| 2017 Q3 | 4.63 Million CAD | -1.3% |
| 2017 Q4 | 7.24 Million CAD | 56.17% |
| 2017 FY | 21.01 Million CAD | 406.19% |
| 2017 Q1 | 4.46 Million CAD | 1075.91% |
| 2016 Q3 | 1.66 Million CAD | 246.48% |
| 2016 Q2 | 481.72 Thousand CAD | -70.29% |
| 2016 Q1 | 1.62 Million CAD | 30.57% |
| 2016 FY | 4.15 Million CAD | -12.72% |
| 2016 Q4 | 379.4 Thousand CAD | -77.27% |
| 2015 Q2 | 1.46 Million CAD | 69.71% |
| 2015 Q4 | 1.24 Million CAD | 4.61% |
| 2015 FY | 4.75 Million CAD | -27.75% |
| 2015 Q3 | 1.18 Million CAD | -18.94% |
| 2015 Q1 | 862.82 Thousand CAD | 139.74% |
| 2014 Q2 | 1.38 Million CAD | -66.54% |
| 2014 Q4 | 359.9 Thousand CAD | -48.7% |
| 2014 Q1 | 4.13 Million CAD | 476.85% |
| 2014 FY | 6.58 Million CAD | 215.15% |
| 2014 Q3 | 701.59 Thousand CAD | -49.32% |
| 2013 FY | 2.08 Million CAD | 42.6% |
| 2013 Q4 | 717.2 Thousand CAD | -22.75% |
| 2013 Q3 | 928.47 Thousand CAD | 312.42% |
| 2013 Q2 | 225.12 Thousand CAD | 3.27% |
| 2013 Q1 | 218 Thousand CAD | 238.22% |
| 2012 Q1 | 334.39 Thousand CAD | 43.04% |
| 2012 FY | 1.46 Million CAD | 11.89% |
| 2012 Q4 | 64.45 Thousand CAD | -88.58% |
| 2012 Q3 | 564.45 Thousand CAD | 12.56% |
| 2012 Q2 | 501.49 Thousand CAD | 49.97% |
| 2011 Q2 | 691.84 Thousand CAD | 127.95% |
| 2011 FY | 1.3 Million CAD | -4.9% |
| 2011 Q1 | 303.51 Thousand CAD | 199.97% |
| 2011 Q4 | 233.77 Thousand CAD | 192.38% |
| 2011 Q3 | 79.95 Thousand CAD | -88.44% |
| 2010 Q1 | 443.41 Thousand CAD | -71.46% |
| 2010 FY | 1.37 Million CAD | 25.86% |
| 2010 Q4 | 101.18 Thousand CAD | -76.43% |
| 2010 Q3 | 429.29 Thousand CAD | 6.63% |
| 2010 Q2 | 402.59 Thousand CAD | -9.21% |
| 2009 FY | 1.09 Million CAD | -33.61% |
| 2009 Q4 | 1.55 Million CAD | 719.51% |
| 2009 Q3 | -250.78 Thousand CAD | -1269.43% |
| 2009 Q2 | -18.31 Thousand CAD | 93.78% |
| 2009 Q1 | -294.34 Thousand CAD | -119.55% |
| 2008 Q2 | 160.41 Thousand CAD | -40.35% |
| 2008 Q3 | -16.05 Thousand CAD | -110.01% |
| 2008 FY | 1.64 Million CAD | 283.74% |
| 2008 Q4 | 1.5 Million CAD | 9479.25% |
| 2008 Q1 | 268.92 Thousand CAD | 372.18% |
| 2007 Q1 | 139 Thousand CAD | -5.26% |
| 2007 Q3 | 64.98 Thousand CAD | -61.39% |
| 2007 Q4 | 56.95 Thousand CAD | -12.36% |
| 2007 Q2 | 168.32 Thousand CAD | 21.1% |
| 2007 FY | 429.26 Thousand CAD | 7.71% |
| 2006 FY | 398.52 Thousand CAD | 0.0% |
| 2006 Q3 | 120.99 Thousand CAD | 88.09% |
| 2006 Q2 | 64.32 Thousand CAD | -14.67% |
| 2006 Q1 | 75.38 Thousand CAD | 0.0% |
| 2006 Q4 | 146.72 Thousand CAD | 21.26% |
| 2005 Q3 | 13.34 Thousand CAD | 81.99% |
| 2005 Q2 | 7334.00 CAD | 225.96% |
| 2005 Q4 | - CAD | -100.0% |
| 2005 FY | - CAD | 0.0% |
| 2005 Q1 | 2250.00 CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bioxytran, Inc. | -8285.00 USD | 173447.483% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 4.248% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -46.639% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -21750.412% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -22.688% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 87.942% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 42155.165% |
| Marizyme, Inc. | 457.7 Thousand USD | -3037.814% |
| Genus plc | 178.7 Million USD | 91.963% |
| Pharming Group N.V. | 220.1 Million USD | 93.475% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -22980.126% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -3401.478% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 130662.173% |
| ContraFect Corporation | -154 Thousand USD | 9425.869% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -18609.812% |
| IMV Inc. | -962.29 Thousand USD | 1592.452% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 3806.271% |
| ONE Bio Corp. | 20.12 Million USD | 28.638% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 64.332% |
| Mesoblast Limited | -35.16 Million USD | 140.838% |
| MultiCell Technologies, Inc. | 49.32 USD | -29119606.002% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 49.171% |
| Genscript Biotech Corporation | 409.55 Million USD | 96.493% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -462886.428% |
| Biomind Labs Inc. | -15.42 Thousand USD | 93213.583% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 1358.076% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -20416.913% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 11658.731% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 290120.981% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 28823.678% |
| Arch Therapeutics, Inc. | -2439.00 USD | 588941.287% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -10121.949% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -29269.814% |
| Q BioMed Inc. | -8988.00 USD | 159889.041% |
| GB Sciences, Inc. | -624.00 USD | 2301676.763% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 16794.377% |
| CSL Limited | 7.56 Billion USD | 99.81% |
| Agentix Corp. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 67.623% |
| Enzolytics Inc. | 30.7 Thousand USD | -46669.047% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -2876.96% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 14827.825% |
| argenx SE | 1.1 Billion USD | 98.704% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 155.67% |
| HST Global, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 6904830.288% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 2891.362% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 162270.72% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -2226.241% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 17228.217% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -1353.655% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -49.431% |
| Kadimastem Ltd | -630.13 Thousand USD | 2379.158% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | 6.892% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 121450.562% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 29859.918% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -8034.254% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -8034.254% |
| Affymax, Inc. | 1.35 Million USD | -958.241% |
| Mobile Lads Corp. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -211.672% |
| CytoDyn Inc. | -29 Thousand USD | 49623.583% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -3091.215% |
| SYBLEU INC | 11.69 Thousand USD | -122692.741% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 4595.0% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 3950.359% |
| Neutra Corp. | 14.33 Thousand USD | -100087.227% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 17614.438% |
| PureTech Health plc | -1.6 Million USD | 995.935% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 1534.411% |
| IXICO plc | 3.27 Million USD | -339.2% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 2169.429% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 901.889% |
| CSL Limited | 7.7 Billion USD | 99.814% |
| Cellectis S.A. | 18 Thousand USD | -79687.994% |